GlossaryMechanismReceptor Antagonist
Mechanism

Receptor Antagonist

Also known as: antagonist · receptor blocker

A receptor antagonist is a molecule that binds a receptor without activating it, blocking the body's own signal or a drug from switching it on.

An antagonist has affinity for a receptor but no efficacy: it sits in or on the receptor and produces no signal of its own. A competitive antagonist occupies the same site as the agonist, so enough extra agonist can outcompete it; on a graph the dose-response curve shifts to the right but still reaches the same top. A non-competitive or irreversible antagonist lowers the maximum response, so adding more agonist cannot fully restore it. A related category, the inverse agonist, pushes a receptor below its resting level of activity rather than just blocking it.

Peptide antagonists are standard research tools. Exendin(9-39)NH2 blocks the GLP-1 receptor and GIP(3-30)NH2 blocks the GIP receptor; by blocking one receptor at a time, researchers have estimated how much of the after-meal insulin response each gut hormone is responsible for. Antibodies can be antagonists too: an antibody that blocks the GIP receptor reduced weight gain in mice and caused weight loss in monkeys, with more weight loss when it was combined with a GLP-1 receptor agonist.

Why it matters

Antagonism explains results that look contradictory. Blocking the GIP receptor reduced weight in animals, even though activating that same receptor is part of the dual-agonist approach used in tirzepatide. Neither direction is settled biology yet, so be wary of anyone who claims one is obviously right.

It also matters when you read mechanism claims. An experiment that uses an antagonist to block a receptor and shows the effect disappears is much stronger evidence that a compound works through that receptor than a correlation is. And antagonists cut both ways: a medicine that blocks a receptor will blunt any peptide that depends on it.

How to tell competitive from non-competitive blocking

  1. Plot the response against agonist concentration, with and without the antagonist.
  2. If the curve shifts to the right but reaches the same maximum, the blocking is competitive.
  3. If the maximum drops and extra agonist cannot restore it, the blocking is non-competitive or irreversible.
  4. For a competitive antagonist, measure how much more agonist you need for the same response (the dose ratio).

Dose ratio = 1 + [antagonist] / KB, where KB is the antagonist concentration that occupies half the receptors (simple competitive antagonism).

Worked example

If KB is 10 nM and the antagonist is present at 90 nM, the dose ratio is 1 + 90 / 10 = 10, so you need 10 times as much agonist to get the same response. At 10 nM antagonist the ratio is 1 + 10 / 10 = 2.

Common mistakes

  • Calling any drug that lowers an effect an antagonist; some act downstream or through a different receptor entirely.
  • Assuming more agonist always overcomes a blocker; that only holds for competitive antagonists.
  • Confusing a neutral antagonist with an inverse agonist, which actively lowers baseline receptor activity.
  • Treating the GIP-receptor antibody results in mice and monkeys as evidence about people.
  • Forgetting that an antagonist used in an experiment is a tool for proving which receptor matters, not a product to take.

Sources

  1. GuidelineInternational Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev, 2003. PMID 14657418.
  2. ReviewEvaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020. PMID 31693916.
  3. Preclinical studyAnti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med, 2018. PMID 30567927.

Page updated . How we grade evidence: methodology.

Related Terms

Receptor Agonist

A receptor agonist is a molecule that binds a receptor and switches it on, producing a response the way the body's own signaling molecule does.

GLP-1 Receptor

The GLP-1 receptor is the G protein-coupled receptor that GLP-1 activates to boost insulin, lower glucagon, slow the stomach and reduce appetite.

GIP Receptor

The GIP receptor is the receptor for GIP, a gut incretin hormone that boosts insulin after meals; tirzepatide activates it along with the GLP-1 receptor.

Look up any peptide term inside DoseCraft Pro

The glossary is just the start. Inside DoseCraft you get 90+ compound deep-dives, a PK-aware protocol engine, interaction checker, and vendor trust scores — every term surfaced in protocol-design context, not a separate page.

Start Free Trial